Hiyasta Tablets (Tucidinostat) Launched in Japan for Relapsed or Refractory ATLL

On October 20, 2021, Meiji Seika Pharma Co., Ltd. announced the launch of Hiyasta Tablets 100 mg (Tucidinostat) in Japan. This novel drug is indicated for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATLL).

Approval and Designation

Hiyasta was designated as an orphan drug by the Ministry of Health, Labour and Welfare (MHLW) in June 2021. The manufacturing and marketing authorization was obtained by Huya Japan, a subsidiary of the U.S.-based HUYABIO International, which developed the drug in collaboration with Meiji Seika Pharma.

Dosage and Administration

The recommended dosage for Hiyasta is 40 mg taken orally once daily, twice a week, with an interval of three or four days between doses. It should be administered after meals.

Clinical Significance

ATLL is an aggressive form of T-cell malignancy with limited treatment options, especially in the relapsed or refractory setting. Hiyasta, an HDAC inhibitor, offers a new oral treatment option that aims to improve clinical outcomes and maintain the quality of life for these patients.

Meiji Seika Pharma stated its commitment to ensuring the appropriate use of Hiyasta and providing essential medical information to healthcare professionals to support patients fighting this rare disease.

Source: Meiji Seika Pharma Press Release - Hiyasta Launch for ATLL

#Leukemia #Lymphoma #ATLL #Hiyasta #Tucidinostat #JapanMedicine #CancerTreatment #OrphanDrug

Figure 1